These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33680104)

  • 1. Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials.
    Huang Y; Jiang Z; Wei Y
    Exp Ther Med; 2021 Apr; 21(4):382. PubMed ID: 33680104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Colacci M; Fralick J; Odutayo A; Fralick M
    Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination.
    Jendle JH; Ampudia-Blasco FJ; Füchtenbusch M; Pozzilli P
    touchREV Endocrinol; 2021 Apr; 17(1):12-20. PubMed ID: 35118442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Li K; Xu G
    J Diabetes; 2019 Aug; 11(8):645-655. PubMed ID: 30565398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin efficacy and safety: a perspective review.
    Anderson SL
    Ther Adv Drug Saf; 2014 Dec; 5(6):242-54. PubMed ID: 25436106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre, prospective, non-interventional study evaluating the safety of dapagliflozin in patients with type 2 diabetes in routine clinical practice in China (DONATE).
    Guo L; Wang J; Li L; Yuan L; Chen S; Wang H; Li T; Qi L; Yang H
    BMC Med; 2023 Jun; 21(1):212. PubMed ID: 37316847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Lu J; Tang L; Meng H; Zhao J; Liang Y
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Network Meta-Analysis of the Dose-Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes.
    Li Y; Li H; Dong L; Lin D; Xu L; Lou P; Zang D; Wang K; Ma L
    Front Endocrinol (Lausanne); 2022; 13():923376. PubMed ID: 35872994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients.
    Wang Y; Hu X; Liu X; Wang Z
    Ther Clin Risk Manag; 2016; 12():1113-31. PubMed ID: 27486328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of two- and twelve-weeks sodium-glucose cotransporter 2 inhibition on DNA and RNA oxidation: two randomized, placebo-controlled trials.
    Larsen EL; Andersen A; Kjær LK; Eickhoff MK; Frimodt-Møller M; Persson F; Rossing P; Lykkesfeldt J; Knop FK; Vilsbøll T; Rungby J; Poulsen HE
    Free Radic Res; 2023 Feb; 57(2):140-151. PubMed ID: 37171199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis.
    El Masri D; Ghosh S; Jaber LA
    Diabetes Res Clin Pract; 2018 Mar; 137():83-92. PubMed ID: 29317332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of metformin and sodium-glucose co-transporter-2 inhibitors in adults with type1 diabetes: A systematic review and network meta-analysis.
    Zhang Q; Wu Y; Lu Y; Fei X
    Rev Clin Esp (Barc); 2020; 220(1):8-21. PubMed ID: 31694774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis.
    Xin Y; Guo Y; Li Y; Ma Y; Li L; Jiang H
    Saudi J Biol Sci; 2019 Feb; 26(2):421-426. PubMed ID: 31485187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor.
    Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z
    Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials.
    Shi FH; Li H; Shen L; Zhang Z; Jiang YH; Hu YM; Liu XY; Gu ZC; Ma J; Lin HW
    Front Pharmacol; 2019; 10():1066. PubMed ID: 31616297
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
    Yavin Y; Mansfield TA; Ptaszynska A; Johnsson K; Parikh S; Johnsson E
    Diabetes Ther; 2016 Mar; 7(1):125-37. PubMed ID: 26758563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study.
    Alguwaihes AM
    Diabetes Ther; 2021 Jul; 12(7):1979-1992. PubMed ID: 34118010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.